{"id":3359,"date":"2025-09-04T17:09:09","date_gmt":"2025-09-04T21:09:09","guid":{"rendered":"http:\/\/www.arraysbank.com\/blog\/?p=3359"},"modified":"2025-09-04T17:44:56","modified_gmt":"2025-09-04T21:44:56","slug":"crpc-castration-resistant-prostate-cancer-primary-with-metastatic-ffpe-tissue-block-pairs","status":"publish","type":"post","link":"https:\/\/www.arraysbank.com\/blog\/crpc-castration-resistant-prostate-cancer-primary-with-metastatic-ffpe-tissue-block-pairs\/","title":{"rendered":"CRPC Primary with Metastatic FFPE Tissue Block Pairs | ArraysBank"},"content":{"rendered":"<h1 data-start=\"266\" data-end=\"391\">Castration-Resistant <a href=\"http:\/\/arraysbank.com\/home\/product\/search.html?keyword=prostate\">Prostate Cancer<\/a> (CRPC) Primary with Metastatic <a href=\"http:\/\/arraysbank.com\/paraffin-tissue-blocks\/sections\">FFPE Tissue Block<\/a> Pairs: A Powerful Research Resource<\/h1>\n<h3>Discover CRPC primary with metastatic FFPE tissue block pairs including IHC results, Gleason score, treatment medication, and serum testosterone levels.<\/h3>\n<h2 data-start=\"393\" data-end=\"410\">Introduction<\/h2>\n<p data-start=\"411\" data-end=\"990\">Castration-Resistant Prostate Cancer (CRPC) represents a major clinical challenge in oncology. Despite androgen deprivation therapy (ADT), some patients experience disease progression, metastasis, and treatment resistance. To advance research, access to <strong data-start=\"665\" data-end=\"733\">paired primary and metastatic prostate cancer FFPE tissue blocks<\/strong> with detailed clinical and pathological data is invaluable. ArraysBank provides <strong data-start=\"814\" data-end=\"865\">CRPC primary-metastatic FFPE tissue block pairs<\/strong>, offering scientists high-quality materials for translational research, biomarker validation, and therapeutic development.<\/p>\n<hr data-start=\"992\" data-end=\"995\" \/>\n<h2 data-start=\"997\" data-end=\"1065\">Key Features of CRPC Primary\u2013Metastatic FFPE Tissue Block Pairs<\/h2>\n<p data-start=\"1066\" data-end=\"1254\">Each set of <strong data-start=\"1078\" data-end=\"1142\">paired formalin-fixed paraffin-embedded (FFPE) tissue blocks<\/strong> is pathologist-verified and annotated with rich clinical metadata, enabling robust scientific investigations.<\/p>\n<ul data-start=\"1256\" data-end=\"1740\">\n<li data-start=\"1256\" data-end=\"1321\">\n<p data-start=\"1258\" data-end=\"1321\"><strong data-start=\"1258\" data-end=\"1319\">Primary tumor and matched metastatic lesion tissue blocks<\/strong><\/p>\n<\/li>\n<li data-start=\"1322\" data-end=\"1398\">\n<p data-start=\"1324\" data-end=\"1398\"><strong data-start=\"1324\" data-end=\"1361\">Immunohistochemical (IHC) results<\/strong> for key prostate cancer biomarkers<\/p>\n<\/li>\n<li data-start=\"1399\" data-end=\"1473\">\n<p data-start=\"1401\" data-end=\"1473\"><strong data-start=\"1401\" data-end=\"1434\">Gleason Score &amp; Gleason Grade<\/strong> for histopathological classification<\/p>\n<\/li>\n<li data-start=\"1474\" data-end=\"1572\">\n<p data-start=\"1476\" data-end=\"1572\"><strong data-start=\"1476\" data-end=\"1508\">Treatment medication history<\/strong> (androgen deprivation therapy, chemotherapy, or novel agents)<\/p>\n<\/li>\n<li data-start=\"1573\" data-end=\"1642\">\n<p data-start=\"1575\" data-end=\"1642\"><strong data-start=\"1575\" data-end=\"1611\">Serum testosterone concentration<\/strong> at recurrence or progression<\/p>\n<\/li>\n<li data-start=\"1643\" data-end=\"1740\">\n<p data-start=\"1645\" data-end=\"1740\"><strong data-start=\"1645\" data-end=\"1684\">Reference range of castration level<\/strong> (e.g., &lt;50 ng\/dL, &lt;20 ng\/dL) for clinical correlation<\/p>\n<\/li>\n<\/ul>\n<p data-start=\"1742\" data-end=\"1876\">This depth of annotation ensures meaningful research outcomes by linking tissue morphology to treatment history and clinical status.<\/p>\n<hr data-start=\"1878\" data-end=\"1881\" \/>\n<h2 data-start=\"1883\" data-end=\"1937\">Why Use Matched Primary\u2013Metastatic Tissue Blocks?<\/h2>\n<p data-start=\"1938\" data-end=\"2057\">Working with <strong data-start=\"1951\" data-end=\"1979\">primary\u2013metastatic pairs<\/strong> provides unique scientific insights not possible from single tumor samples:<\/p>\n<ul data-start=\"2059\" data-end=\"2559\">\n<li data-start=\"2059\" data-end=\"2195\">\n<p data-start=\"2061\" data-end=\"2195\"><strong data-start=\"2061\" data-end=\"2093\">Disease progression analysis<\/strong> \u2013 Study the molecular and morphological changes from primary prostate tumors to metastatic lesions.<\/p>\n<\/li>\n<li data-start=\"2196\" data-end=\"2340\">\n<p data-start=\"2198\" data-end=\"2340\"><strong data-start=\"2198\" data-end=\"2231\">Therapy resistance mechanisms<\/strong> \u2013 Correlate pre- and post-treatment IHC profiles with serum testosterone levels and castration thresholds.<\/p>\n<\/li>\n<li data-start=\"2341\" data-end=\"2457\">\n<p data-start=\"2343\" data-end=\"2457\"><strong data-start=\"2343\" data-end=\"2367\">Biomarker validation<\/strong> \u2013 Validate novel markers across primary and metastatic samples within the same patient.<\/p>\n<\/li>\n<li data-start=\"2458\" data-end=\"2559\">\n<p data-start=\"2460\" data-end=\"2559\"><strong data-start=\"2460\" data-end=\"2484\">Clinical translation<\/strong> \u2013 Support research aligned with real-world castration-resistant disease.<\/p>\n<\/li>\n<\/ul>\n<hr data-start=\"2561\" data-end=\"2564\" \/>\n<h2 data-start=\"2566\" data-end=\"2611\">Applications in Prostate Cancer Research<\/h2>\n<p data-start=\"2612\" data-end=\"2665\">The <strong data-start=\"2616\" data-end=\"2641\">CRPC FFPE block pairs<\/strong> are highly versatile:<\/p>\n<ul data-start=\"2667\" data-end=\"3045\">\n<li data-start=\"2667\" data-end=\"2747\">\n<p data-start=\"2669\" data-end=\"2747\"><strong data-start=\"2669\" data-end=\"2701\">Oncology biomarker discovery<\/strong> \u2013 Identify molecular drivers of metastasis.<\/p>\n<\/li>\n<li data-start=\"2748\" data-end=\"2831\">\n<p data-start=\"2750\" data-end=\"2831\"><strong data-start=\"2750\" data-end=\"2770\">Drug development<\/strong> \u2013 Evaluate new therapies in castration-resistant contexts.<\/p>\n<\/li>\n<li data-start=\"2832\" data-end=\"2921\">\n<p data-start=\"2834\" data-end=\"2921\"><strong data-start=\"2834\" data-end=\"2857\">Pathology education<\/strong> \u2013 Train medical professionals using annotated case materials.<\/p>\n<\/li>\n<li data-start=\"2922\" data-end=\"3045\">\n<p data-start=\"2924\" data-end=\"3045\"><strong data-start=\"2924\" data-end=\"2947\">Comparative studies<\/strong> \u2013 Contrast IHC, Gleason grades, and treatment responses between primary and metastatic samples.<\/p>\n<\/li>\n<\/ul>\n<hr data-start=\"3047\" data-end=\"3050\" \/>\n<h2 data-start=\"3052\" data-end=\"3093\">Quality and Compliance at ArraysBank<\/h2>\n<p data-start=\"3094\" data-end=\"3181\">ArraysBank ensures every specimen undergoes rigorous <strong data-start=\"3147\" data-end=\"3178\">multi-layer quality control<\/strong>:<\/p>\n<ul data-start=\"3183\" data-end=\"3415\">\n<li data-start=\"3183\" data-end=\"3225\">\n<p data-start=\"3185\" data-end=\"3225\"><strong data-start=\"3185\" data-end=\"3223\">Ethical and IRB-compliant sourcing<\/strong><\/p>\n<\/li>\n<li data-start=\"3226\" data-end=\"3282\">\n<p data-start=\"3228\" data-end=\"3282\"><strong data-start=\"3228\" data-end=\"3256\">Pathologist confirmation<\/strong> of tumor type and grade<\/p>\n<\/li>\n<li data-start=\"3283\" data-end=\"3337\">\n<p data-start=\"3285\" data-end=\"3337\"><strong data-start=\"3285\" data-end=\"3311\">H&amp;E and IHC validation<\/strong> to confirm antigenicity<\/p>\n<\/li>\n<li data-start=\"3338\" data-end=\"3415\">\n<p data-start=\"3340\" data-end=\"3415\"><strong data-start=\"3340\" data-end=\"3391\">Controlled storage and FedEx overnight shipping<\/strong> to maintain integrity<\/p>\n<\/li>\n<\/ul>\n<p data-start=\"3417\" data-end=\"3510\">Researchers can rely on <strong data-start=\"3441\" data-end=\"3507\">consistent, reproducible, and well-documented tissue resources<\/strong>.<\/p>\n<hr data-start=\"3512\" data-end=\"3515\" \/>\n<h2 data-start=\"3517\" data-end=\"3532\">Conclusion<\/h2>\n<p data-start=\"3533\" data-end=\"3941\">ArraysBank\u2019s <strong data-start=\"3546\" data-end=\"3602\">CRPC primary with metastatic FFPE tissue block pairs<\/strong> provide unparalleled value for prostate cancer research. With <strong data-start=\"3665\" data-end=\"3807\">Gleason scores, Gleason grades, treatment medication history, serum testosterone concentrations, and reference ranges of castration levels<\/strong>, these annotated samples empower investigators to study disease mechanisms, resistance pathways, and potential therapeutic targets.<\/p>\n<p data-start=\"3533\" data-end=\"3941\">Explore more about our <a class=\"decorated-link cursor-pointer\" rel=\"noopener\" data-start=\"3968\" data-end=\"4017\">tissue array and FFPE solutions<\/a> and discover how ArraysBank can accelerate your prostate cancer research.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<figure id=\"attachment_3360\" aria-describedby=\"caption-attachment-3360\" style=\"width: 2410px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-3360 size-full\" src=\"https:\/\/www.arraysbank.com\/blog\/wp-content\/uploads\/2025\/08\/CRPC-Castration-Resistant-Prostate-Cancer-Primary-and-Metastatic-FFPE-Tissue-Blocks.png\" alt=\"CRPC (Castration-Resistant Prostate Cancer) Primary and Metastatic FFPE Tissue Blocks\" width=\"2410\" height=\"1113\" srcset=\"https:\/\/www.arraysbank.com\/blog\/wp-content\/uploads\/2025\/08\/CRPC-Castration-Resistant-Prostate-Cancer-Primary-and-Metastatic-FFPE-Tissue-Blocks.png 2410w, https:\/\/www.arraysbank.com\/blog\/wp-content\/uploads\/2025\/08\/CRPC-Castration-Resistant-Prostate-Cancer-Primary-and-Metastatic-FFPE-Tissue-Blocks-300x139.png 300w, https:\/\/www.arraysbank.com\/blog\/wp-content\/uploads\/2025\/08\/CRPC-Castration-Resistant-Prostate-Cancer-Primary-and-Metastatic-FFPE-Tissue-Blocks-1024x473.png 1024w, https:\/\/www.arraysbank.com\/blog\/wp-content\/uploads\/2025\/08\/CRPC-Castration-Resistant-Prostate-Cancer-Primary-and-Metastatic-FFPE-Tissue-Blocks-768x355.png 768w, https:\/\/www.arraysbank.com\/blog\/wp-content\/uploads\/2025\/08\/CRPC-Castration-Resistant-Prostate-Cancer-Primary-and-Metastatic-FFPE-Tissue-Blocks-1536x709.png 1536w, https:\/\/www.arraysbank.com\/blog\/wp-content\/uploads\/2025\/08\/CRPC-Castration-Resistant-Prostate-Cancer-Primary-and-Metastatic-FFPE-Tissue-Blocks-2048x946.png 2048w\" sizes=\"auto, (max-width: 2410px) 100vw, 2410px\" \/><figcaption id=\"caption-attachment-3360\" class=\"wp-caption-text\">CRPC (Castration-Resistant Prostate Cancer) Primary and Metastatic FFPE Tissue Blocks<\/figcaption><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Castration-Resistant Prostate Cancer (CRPC) Primary with Metastatic FFPE Tissue Block Pairs: A Powerful Research Resource Discover CRPC primary with metastatic FFPE tissue block pairs including IHC results, Gleason score, treatment medication, and serum testosterone levels. Introduction Castration-Resistant Prostate Cancer (CRPC) represents a major clinical challenge in oncology. Despite androgen deprivation therapy (ADT), some patients experience [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3363,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[15],"tags":[],"class_list":["post-3359","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tissue-block-section"],"blocksy_meta":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/posts\/3359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/comments?post=3359"}],"version-history":[{"count":5,"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/posts\/3359\/revisions"}],"predecessor-version":[{"id":3382,"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/posts\/3359\/revisions\/3382"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/media\/3363"}],"wp:attachment":[{"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/media?parent=3359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/categories?post=3359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arraysbank.com\/blog\/wp-json\/wp\/v2\/tags?post=3359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}